相关实验视频

Updated: May 23, 2025

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

化学Ad5/35性腺病毒克服了先前存在的中和抗体,并提高了瘤向效率

Zhoutong Dai^1,2, Yao Si^1,2, Shengfeng Xiong^1,2

¹Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Cancer gene therapy

|March 8, 2025

概括

一种新的瘤性腺病毒,oAd5/35-HF,通过修改囊蛋白来克服先前存在的中和抗体. 这提高了对各种癌症的瘤性病毒疗法的疗效.

科学领域:

瘤治疗性病毒疗法
亚地诺病毒载体工程学
癌症免疫学癌症免疫学

背景情况:

基于结核病毒的腺病毒血清型5 (Ad5) 面临着由于高预先存在的中和抗体 (NAB) 患病率的挑战.
人口中的很大一部分对Ad5具有抗体,限制了基于Ad5的疗法的有效性.

研究的目的:

开发第四代性腺病毒载体,oAd5/35-HF,能够逃避预先存在的中和抗体并提高感染效率.
为瘤性腺病毒和基于腺病毒载体的疫苗创建一个多功能平台.

主要方法:

通过将腺病毒血清型5 (Ad5) 的1号和5号六进制高变区 (HVRs) 替换为腺病毒血清型35 (Ad35) 的区域,改造了oAd5/35-HF.
修改了腺病毒载体的纤维区域.
评估了感染效率,病毒标位和对中和抗体 (NAB) 的耐药性.

主要成果:

oAd5/35-HF 载体显著提高了感染效率.
在修改后保持高的病毒标位.
改造后的病毒有效地抵抗了先前存在的中和抗体 (NAB).
在多种癌症类型中表现出强大的抗瘤活性,即使NAB水平高.

结论:

oAd5/35-HF代表了一种新奇的虚构体瘤性腺病毒,具有针对癌症的增强疗效.
这种载体平台显示出克服Ad5免疫力和推进菌性病毒疗法和疫苗开发的前景.

更多相关视频

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.